Biography
Professional Summary
Education & Certifications
- Fellowship: University of Utah School of Medicine (2006) UT
- Board Certification: American Board of Psychiatry and Neurology, Neurology (2005)
- Residency: University of Utah School of Medicine (2004) UT
- Internship: University of Utah School of Medicine (2001) UT
- Medical Education: University of Alabama at Birmingham (2000) AL
- Fellowship, University of Utah School of Medicine, Neurogenetics (2006)
- Residency, University of Utah School of Medicine, Neurology (2004)
- Internship, University of Utah School of Medicine, Internal Medicine (2001)
- PhD, University of Alabama, Biochemistry (1999)
- MD, University of Alabama School of Medicine, Medical Degree (2000)
Honors & Awards
- Stephen Q. Shafer Award for Humanism in Neurology, Columbia University Neurology Residents (2014)
Publications
-
Mutational Spectrum of DMD Mutations in Dystrophinopathy Patients: Application of Modern Diagnostic Techniques to a Large Cohort
Flanigan, K. M., Dunn, D. M., von Niederhausern, A., Soltanzadeh, P., Gappmaier, E., Howard, M. T., … Weiss, R. B. (2009). Mutational Spectrum of DMD Mutations in Dystrophinopathy Patients: Application of Modern Diagnostic Techniques to a Large Cohort. HUMAN MUTATION, 30(12), 1657–1666. -
Human Dermal Fibroblasts Derived from Oculodentodigital Dysplasia Patients Suggest That Patients May Have Wound-Healing Defects
Churko, J. M., Shao, Q., Gong, X.-Q., Swoboda, K. J., Bai, D., Sampson, J., & Laird, D. W. (2011). Human Dermal Fibroblasts Derived from Oculodentodigital Dysplasia Patients Suggest That Patients May Have Wound-Healing Defects. HUMAN MUTATION, 32(4), 456–466. -
Nonsense Mutation-Associated Becker Muscular Dystrophy: Interplay Between Exon Definition and Splicing Regulatory Elements within the DMD Gene
Flanigan, K. M., Dunn, D. M., von Niederhausern, A., Soltanzadeh, P., Howard, M. T., Sampson, J. B., … Weiss, R. B. (2011). Nonsense Mutation-Associated Becker Muscular Dystrophy: Interplay Between Exon Definition and Splicing Regulatory Elements within the DMD Gene. HUMAN MUTATION, 32(3), 299–308. -
The G60S Cx43 mutant enhances keratinocyte proliferation and differentiation
Churko, J. M., Kelly, J. J., Macdonald, A., Lee, J., Sampson, J., Bai, D., & Laird, D. W. (2012). The G60S Cx43 mutant enhances keratinocyte proliferation and differentiation. EXPERIMENTAL DERMATOLOGY, 21(8), 612–618. -
ATALUREN TREATMENT OF PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY
Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., Comi, G. P., … McDonald, C. M. (2014). ATALUREN TREATMENT OF PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY. MUSCLE & NERVE, 50(4), 477–487. -
Nuclear localization of SMN and FUS is not altered in fibroblasts from patients with sporadic ALS
Kariya, S., Sampson, J. B., Northrop, L. E., Lucarelli, C. M., Naini, A. B., Re, D. B., … Mitsumoto, H. (2014). Nuclear localization of SMN and FUS is not altered in fibroblasts from patients with sporadic ALS. AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 15(7-8), 581–587. -
Clinical and genetic characterization of manifesting carriers of DMD mutations
Soltanzadeh, P., Friez, M. J., Dunn, D., von Niederhausern, A., Gurvich, O. L., Swoboda, K. J., … Flanigan, K. M. (2010). Clinical and genetic characterization of manifesting carriers of DMD mutations. NEUROMUSCULAR DISORDERS, 20(8), 499–504. -
Identification of Uncommon Recurrent Potocki-Lupski Syndrome-Associated Duplications and the Distribution of Rearrangement Types and Mechanisms in PTLS
Zhang, F., Potocki, L., Sampson, J. B., Liu, P., Sanchez-Valle, A., Robbins-Furman, P., … Lupski, J. R. (2010). Identification of Uncommon Recurrent Potocki-Lupski Syndrome-Associated Duplications and the Distribution of Rearrangement Types and Mechanisms in PTLS. AMERICAN JOURNAL OF HUMAN GENETICS, 86(3), 462–470. -
Paraneoplastic myopathy: response to intravenous immunoglobulin
Sampson, J. B., Smith, S. M., Smith, A. G., Singleton, J. R., Chin, S., Pestronk, A., & Flanigan, K. M. (2007). Paraneoplastic myopathy: response to intravenous immunoglobulin. NEUROMUSCULAR DISORDERS, 17(5), 404–408. -
Inhibition of human surfactant protein a function by oxidation intermediates of nitrite
Davis, I. C., Zhu, S., Sampson, J. B., Crow, J. P., & Matalon, S. (2002). Inhibition of human surfactant protein a function by oxidation intermediates of nitrite. FREE RADICAL BIOLOGY AND MEDICINE, 33(12), 1703–1713. -
Liposome-delivered superoxide dismutase prevents nitric oxide-dependent motor neuron death induced by trophic factor withdrawal
Estevez, A. G., Sampson, J. B., Zhuang, Y. X., Spear, N., Richardson, G. J., Crow, J. P., … Beckman, J. S. (2000). Liposome-delivered superoxide dismutase prevents nitric oxide-dependent motor neuron death induced by trophic factor withdrawal. FREE RADICAL BIOLOGY AND MEDICINE, 28(3), 437–446. -
Myeloperoxidase and horseradish peroxidase catalyze tyrosine nitration in proteins from nitrite and hydrogen peroxide
Sampson, J. B., Ye, Y. Z., Rosen, H., & Beckman, J. S. (1998). Myeloperoxidase and horseradish peroxidase catalyze tyrosine nitration in proteins from nitrite and hydrogen peroxide. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 356(2), 207–213. -
DIFFERENTIAL MODULATION OF ASTROCYTE CYTOKINE GENE-EXPRESSION BY TGF-BETA
Benveniste, E. N., Kwon, J. B., Chung, W. J., Sampson, J., Pandya, K., & Tang, L. P. (1994). DIFFERENTIAL MODULATION OF ASTROCYTE CYTOKINE GENE-EXPRESSION BY TGF-BETA. JOURNAL OF IMMUNOLOGY, 153(11), 5210–5221. -
Manipulating Cx43 expression triggers gene reprogramming events in dermal fibroblasts from oculodentodigital dysplasia patients.
Esseltine, J. L., Shao, Q., Huang, T., Kelly, J. J., Sampson, J., & Laird, D. W. (2015). Manipulating Cx43 expression triggers gene reprogramming events in dermal fibroblasts from oculodentodigital dysplasia patients. Biochemical Journal, 472(1), 55–69. -
Specific functional pathologies of Cx43 mutations associated with oculodentodigital dysplasia.
Kelly, J. J., Esseltine, J. L., Shao, Q., Jabs, E. W., Sampson, J., Auranen, M., … Laird, D. W. (2016). Specific functional pathologies of Cx43 mutations associated with oculodentodigital dysplasia. Molecular Biology of the Cell, 27(14), 2172–85. -
A 31-Year-Old Man With a Ring-Enhancing Brain Lesion.
Riley, C. S., Roth, L. A., Sampson, J. B., Radhakrishnan, J., Herlitz, L. C., Blitz, A. M., & Moazami, G. (2017). A 31-Year-Old Man With a Ring-Enhancing Brain Lesion. Journal of Neuro-Ophthalmology . -
Loss-of-Function Mutations in LGI4, a Secreted Ligand Involved in Schwann Cell Myelination, Are Responsible for Arthrogryposis Multiplex Congenita
Xue, S., Maluenda, J., Marguet, F., Shboul, M., Quevarec, L., Bonnard, C., … Melki, J. (2017). Loss-of-Function Mutations in LGI4, a Secreted Ligand Involved in Schwann Cell Myelination, Are Responsible for Arthrogryposis Multiplex Congenita. AMERICAN JOURNAL OF HUMAN GENETICS, 100(4), 659–65. -
Increased EEG Theta Spectral Power in Sleep in Myotonic Dystrophy Type 1.
Cheung, J., Ruoff, C., Moore, H., Hagerman, K. A., Perez, J., Sakamuri, S., … Sampson, J. (2018). Increased EEG Theta Spectral Power in Sleep in Myotonic Dystrophy Type 1. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine, 14(2), 229–35. -
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., … Finkel, R. S. (2018). Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. NEW ENGLAND JOURNAL OF MEDICINE, 378(7), 625–35. -
Minimally Invasive Thymectomy and Lung Volume Reduction in a Patient with Myasthenia Gravis.
Salna, M., Kidambi, S., Sampson, J., & Shrager, J. B. (2018). Minimally Invasive Thymectomy and Lung Volume Reduction in a Patient with Myasthenia Gravis. The Annals of Thoracic Surgery. -
FGFR3 Antibodies in Neuropathy: What to Do With Them?
Samara, V., Sampson, J., & Muppidi, S. (2018). FGFR3 Antibodies in Neuropathy: What to Do With Them? Journal of Clinical Neuromuscular Disease, 20(1), 35–40. -
Modeling Cx43-linked pathologies in the human context
Esseltine, J. L., Shao, Q., Brooks, C., Sampson, J., Betts, D. H., & Seguin, C. (2015). Modeling Cx43-linked pathologies in the human context. MOLECULAR BIOLOGY OF THE CELL, 26. -
Basal Ganglia Gliosis in a Case of Rapid-Onset Dystonia-Parkinsonism (DYT12) with a Novel Mutation in ATPase 1A3 (ATP1A3)
Sampson, J. B., Michaeli, T. H., Wright, B. A., Goldman, J. E., Vonsattel, J.-P., & Fahn, S. (2016). Basal Ganglia Gliosis in a Case of Rapid-Onset Dystonia-Parkinsonism (DYT12) with a Novel Mutation in ATPase 1A3 (ATP1A3). MOVEMENT DISORDERS CLINICAL PRACTICE, 3(6), 618–20. -
C-terminal proline deletions in KCNC3 cause delayed channel inactivation and an adult-onset progressive SCA13 with spasticity
Khare, S., Galeano, K., Zhang, Y., Nick, J. A., Nick, H. S., Subramony, S. H., … Waters, M. F. (2018). C-terminal proline deletions in KCNC3 cause delayed channel inactivation and an adult-onset progressive SCA13 with spasticity. CEREBELLUM, 17(5), 692–97. -
Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease.
Splinter, K., Adams, D. R., Bacino, C. A., Bellen, H. J., Bernstein, J. A., Cheatle-Jarvela, A. M., … Ashley, E. A. (2018). Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease. The New England Journal of Medicine. -
Experience using Spinraza to treat adults with spinal muscular atrophy
Day, J., Wolford, C., Macpherson, C., Hagerman, K., Paulose, S., Zeineh, M., … Duong, T. (2018). Experience using Spinraza to treat adults with spinal muscular atrophy. NEUROMUSCULAR DISORDERS, 28, S81. -
Nusinersen Efficacy in Adults with Spinal Muscular Atrophy
Day, J., Wolford, C., MacPherson, C., Martens, W., McDermott, M., Darras, B., … Duong, T. (2018). Nusinersen Efficacy in Adults with Spinal Muscular Atrophy. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
FGFR3 Antibodies in Neuropathy. What to do with them?
Samara, V., Sampson, J., & Muppidi, S. (2018). FGFR3 Antibodies in Neuropathy. What to do with them? NEUROLOGY, 90. -
Consensus-based care recommendations for adults with myotonic dystrophy type 1
Ashizawa, T., Gagnon, C., Groh, W. J., Gutmann, L., Johnson, N. E., Meola, G., … Winblad, S. (2018). Consensus-based care recommendations for adults with myotonic dystrophy type 1. NEUROLOGY-CLINICAL PRACTICE, 8(6), 507–20. -
Developing a genomics rotation: Practical training around variant interpretation for genetic counseling students.
Grove, M. E., White, S., Fisk, D. G., Rego, S., Dagan-Rosenfeld, O., Kohler, J. N., … Hanson-Kahn, A. K. (2019). Developing a genomics rotation: Practical training around variant interpretation for genetic counseling students. Journal of Genetic Counseling. -
A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis.
Hom, J., Marwaha, S., Postolova, A., Kittle, J., Vasquez, R., Davidson, J., … Wheeler, M. (2019). A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis. Journal of General Internal Medicine. -
Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening.
Glascock, J., Sampson, J., Haidet-Phillips, A., Connolly, A., Darras, B., Day, J., … Jarecki, J. (2018). Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening. Journal of Neuromuscular Diseases, 5(2), 145–58. -
Extracutaneous manifestations in phacomatosis cesioflammea and cesiomarmorata: Case series and literature review.
Kumar, A., Zastrow, D. B., Kravets, E. J., Beleford, D., Ruzhnikov, M. R., Grove, M. E., … Bernstein, J. A. (2019). Extracutaneous manifestations in phacomatosis cesioflammea and cesiomarmorata: Case series and literature review. American Journal of Medical Genetics. Part A. -
A toolkit for genetics providers in follow-up of patients with non-diagnostic exome sequencing.
Zastrow, D. B., Kohler, J. N., Bonner, D., Reuter, C. M., Fernandez, L., Grove, M. E., … Wheeler, M. T. (2019). A toolkit for genetics providers in follow-up of patients with non-diagnostic exome sequencing. Journal of Genetic Counseling, 28(2), 213–28. -
Basal Ganglia Gliosis in a Case of Rapid-Onset Dystonia-Parkinsonism (DYT12) with a Novel Mutation in ATPase 1A3 (ATP1A3).
Sampson, J. B., Michaeli, T. H., Wright, B. A., Goldman, J. E., Vonsattel, J.-P. P., & Fahn, S. (2016). Basal Ganglia Gliosis in a Case of Rapid-Onset Dystonia-Parkinsonism (DYT12) with a Novel Mutation in ATPase 1A3 (ATP1A3). Movement Disorders Clinical Practice, 3(6), 618–620. -
A toolkit for genetics providers in follow-up of patients with non-diagnostic exome sequencing
Zastrow, D. B., Kohler, J. N., Bonner, D., Reuter, C. M., Fernandez, L., Grove, M. E., … Zheng, A. (2019). A toolkit for genetics providers in follow-up of patients with non-diagnostic exome sequencing. JOURNAL OF GENETIC COUNSELING, 28(2), 213–28. -
Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease
Splinter, K., Adams, D. R., Bacino, C. A., Bellen, H. J., Bernstein, J. A., Cheatle-Jarvela, A. M., … Ashley, E. A. (2018). Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease. NEW ENGLAND JOURNAL OF MEDICINE, 379(22), 2131–39. -
Developing a genomics rotation: Practical training around variant interpretation for genetic counseling students
Grove, M. E., White, S., Fisk, D. G., Rego, S., Dagan-Rosenfeld, O., Kohler, J. N., … Hanson-Kahn, A. K. (2019). Developing a genomics rotation: Practical training around variant interpretation for genetic counseling students. JOURNAL OF GENETIC COUNSELING, 28(2), 466–76. -
Minimally Invasive Thymectomy and Lung Volume Reduction in a Patient With Myasthenia Gravis
Salna, M., Kidambi, S., Sampson, J., & Shrager, J. B. (2018). Minimally Invasive Thymectomy and Lung Volume Reduction in a Patient With Myasthenia Gravis. ANNALS OF THORACIC SURGERY, 106(6), E313–E315. -
Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts.
Frésard, L., Smail, C., Ferraro, N. M., Teran, N. A., Li, X., Smith, K. S., … Montgomery, S. B. (2019). Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. Nature Medicine. -
Extracutaneous manifestations in phacomatosis cesioflammea and cesiomarmorata: Case series and literature review
Kumar, A., Zastrow, D. B., Kravets, E. J., Beleford, D., Ruzhnikov, M. R. Z., Grove, M. E., … Zheng, A. (2019). Extracutaneous manifestations in phacomatosis cesioflammea and cesiomarmorata: Case series and literature review. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 179(6), 966–77. -
A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis
Hom, J., Marwaha, S., Postolova, A., Kittle, J., Vasquez, R., Davidson, J., … Wheeler, M. (2019). A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis. JOURNAL OF GENERAL INTERNAL MEDICINE, 34(6), 1058–62. -
Nusinersen Efficacy in Adults with Spinal Muscular Atrophy
Day, J., Wolford, C., MacPherson, C., Martens, W., McDermott, M., Darras, B., … Duong, T. (2019). Nusinersen Efficacy in Adults with Spinal Muscular Atrophy. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy Through Newborn Screening
Glascock, J., Sampson, J., Haidet-Phillips, A., Connolly, A., Darras, B., Day, J., … Jarecki, J. (2019). Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy Through Newborn Screening. NEUROLOGY, 92(15). -
Genomics in medicine: a novel elective rotation for internal medicine residents.
Geng, L. N., Kohler, J. N., Levonian, P., Bernstein, J. A., Ford, J. M., Ahuja, N., … Wheeler, M. (2019). Genomics in medicine: a novel elective rotation for internal medicine residents. Postgraduate Medical Journal. -
Connexin43 is Dispensable for Early Stage Human Mesenchymal Stem Cell Adipogenic Differentiation But is Protective against Cell Senescence.
Shao, Q., Esseltine, J. L., Huang, T., Novielli-Kuntz, N., Ching, J. E., Sampson, J., & Laird, D. W. (2019). Connexin43 is Dispensable for Early Stage Human Mesenchymal Stem Cell Adipogenic Differentiation But is Protective against Cell Senescence. Biomolecules, 9(9). -
Multiomics Approach to Diagnosing Undiagnosed Patients
Wheeler, M. T., Kohler, J. N., Bonner, D. E., Zastrow, D. B., Reuter, C., Majcherska, M., … Bernstein, J. A. (2019). Multiomics Approach to Diagnosing Undiagnosed Patients. EUROPEAN JOURNAL OF HUMAN GENETICS, 27, 1163–64. -
Dynamic regulation of connexins in stem cell pluripotency.
Esseltine, J. L., Brooks, C. R., Edwards, N. A., Subasri, M., Sampson, J., Séguin, C., … Laird, D. W. (2019). Dynamic regulation of connexins in stem cell pluripotency. Stem Cells (Dayton, Ohio). -
Explaining RLS families using risk SNPs from GWAS
Tilch, E., Zhao, C., Salminen, A., Antic, A., Schormair, B., Oexle, K., … Winkelmann, J. (2019). Explaining RLS families using risk SNPs from GWAS. EUROPEAN JOURNAL OF HUMAN GENETICS, 27, 658–59. -
Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2.
Glascock, J., Sampson, J., Connolly, A. M., Darras, B. T., Day, J. W., Finkel, R., … Jarecki, J. (2020). Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2. Journal of Neuromuscular Diseases. -
Successful liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
Kripps, K. A., Nakayuenyongsuk, W., Shayota, B. J., Berquist, W., Gomez-Ospina, N., Esquivel, C. O., … Larson, A. A. (2020). Successful liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Molecular Genetics and Metabolism. -
De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation.
Mao, D., Reuter, C. M., Ruzhnikov, M. R., Beck, A. E., Farrow, E. G., Emrick, L. T., … Chao, H.-T. T. (2020). De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation. American Journal of Human Genetics. -
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.
Campbell, C., Barohn, R. J., Bertini, E., Chabrol, B., Comi, G. P., Darras, B. T., … Muntoni, F. (2020). Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research. -
Diagnosis of Myotonic Dystrophy Based on Resting State fMRI Using Convolutional Neural Networks.
Kamali, T., Hagerman, K. A., Day, J. W., Sampson, J., Lim, K. O., Mueller, B. A., & Wozniak, J. (2020). Diagnosis of Myotonic Dystrophy Based on Resting State fMRI Using Convolutional Neural Networks. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2020, 1714–17. -
Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science.
Schoch, K., Esteves, C., Bican, A., Spillmann, R., Cope, H., McConkie-Rosell, A., … Shashi, V. (2020). Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science. Genetics in Medicine : Official Journal of the American College of Medical Genetics. -
Increased EEG theta spectral power in polysomnography of myotonic dystrophy type 1 compared to matched controls.
Ruoff, C., Cheung, J., Perez, J., Sakamuri, S., Mignot, E., Day, J., & Sampson, J. (2017). Increased EEG theta spectral power in polysomnography of myotonic dystrophy type 1 compared to matched controls. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Transcriptome alterations in myotonic dystrophy frontal cortex.
Otero, B. A., Poukalov, K., Hildebrandt, R. P., Thornton, C. A., Jinnai, K., Fujimura, H., … Wang, E. T. (2021). Transcriptome alterations in myotonic dystrophy frontal cortex. Cell Reports, 34(3), 108634. -
Commonalities across computational workflows for uncovering explanatory variants in undiagnosed cases.
Kobren, S. N., Baldridge, D., Velinder, M., Krier, J. B., LeBlanc, K., Esteves, C., … Kohane, I. S. (2021). Commonalities across computational workflows for uncovering explanatory variants in undiagnosed cases. Genetics in Medicine : Official Journal of the American College of Medical Genetics. -
Diagnosis of Myotonic Dystrophy Based on Resting State fMRI Using Convolutional Neural Networks
Kamali, T., Hagerman, K. A., Day, J. W., Sampson, J., Lim, K. O., Mueller, B. A., & Wozniak, J. (2020). Diagnosis of Myotonic Dystrophy Based on Resting State fMRI Using Convolutional Neural Networks. 42ND ANNUAL INTERNATIONAL CONFERENCES OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY: ENABLING INNOVATIVE TECHNOLOGIES FOR GLOBAL HEALTHCARE EMBC'20. IEEE. -
Exome testing most useful for people with recessive CMT
Siskind, C., Sampson, J., Goyal, N., Rocha, A. C. T., & Day, J. (2021). Exome testing most useful for people with recessive CMT. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. WILEY. -
Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain
Marbach, F., Stoyanov, G., Erger, F., Stratakis, C. A., Settas, N., London, E., … Schaaf, C. P. (2021). Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain. GENETICS IN MEDICINE. -
A resource of lipidomics and metabolomics data from individuals with undiagnosed diseases
Kyle, J. E., Stratton, K. G., Zink, E. M., Kim, Y.-M., Bloodsworth, K. J., Monroe, M. E., … Metz, T. O. (2021). A resource of lipidomics and metabolomics data from individuals with undiagnosed diseases. SCIENTIFIC DATA, 8(1), 114. -
Dominant and Recessive Congenital Myasthenic Syndromes Caused by SYT2 Mutations.
Maselli, R. A., Wei, D. T., Hodgson, T. S., Sampson, J., Vazquez, J., Smith, H. L., … Ferns, M. (2021). Dominant and Recessive Congenital Myasthenic Syndromes Caused by SYT2 Mutations. Muscle & Nerve. -
Advances in the therapy of Spinal Muscular Atrophy.
Klotz, J., Rocha, C. T., Young, S. D., Duong, T., Buu, M. M., Sampson, J., & Day, J. W. (2021). Advances in the therapy of Spinal Muscular Atrophy. The Journal of Pediatrics. -
Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation.
Beijer, D., Kim, H. J., Guo, L., O'Donovan, K., Mademan, I., Deconinck, T., … Baets, J. (2021). Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation. JCI Insight, 6(14). -
A variant of uncertain significance in SDHAF1, the succinate dehydrogenase chaperone protein, in an adult patient with spastic paraparesis and leukoencephalopathy.
Vlahovic, L., Lock, C. B., Han, M. H., Van Haren, K., & Sampson, J. B. (2021). A variant of uncertain significance in SDHAF1, the succinate dehydrogenase chaperone protein, in an adult patient with spastic paraparesis and leukoencephalopathy. Multiple Sclerosis and Related Disorders, 54, 103132. -
Genetic counselor roles in the undiagnosed diseases network research study: Clinical care, collaboration, and curation.
Kohler, J. N., Kelley, E. G., Boyd, B. M., Sillari, C. H., Marwaha, S., & Wheeler, M. T. (2021). Genetic counselor roles in the undiagnosed diseases network research study: Clinical care, collaboration, and curation. Journal of Genetic Counseling. -
Nusinersen Treatment in Adults With Spinal Muscular Atrophy.
Duong, T., Wolford, C., McDermott, M. P., Macpherson, C. E., Pasternak, A., Glanzman, A. M., … Day, J. W. (2021). Nusinersen Treatment in Adults With Spinal Muscular Atrophy. Neurology. Clinical Practice, 11(3), e317–e327. -
Leriglitazone Reduces Cerebral Lesions and Improves Biomarkers Related to Axonal Degeneration, Inflammation and Compromised Blood-Brain-Barrier in Patients with Adrenomyeloneuropathy
Mochel, F., Eichler, F., Engelen, M., Lachman, R., Fatemi, A., Sampson, J., … Kohler, W. (2021). Leriglitazone Reduces Cerebral Lesions and Improves Biomarkers Related to Axonal Degeneration, Inflammation and Compromised Blood-Brain-Barrier in Patients with Adrenomyeloneuropathy. ANNALS OF NEUROLOGY. WILEY. -
Results of Double-blind, Placebo-controlled, Dose Range Finding, Crossover Study of Single Day Administration of ERX-963 (IV Flumazenil) in Adults with Myotonic Dystrophy Type 1
Sampson, J., Wang, E., Day, J., Gutmann, L., Mezerhane, E., Seto, A., & Ehrich, E. (2021). Results of Double-blind, Placebo-controlled, Dose Range Finding, Crossover Study of Single Day Administration of ERX-963 (IV Flumazenil) in Adults with Myotonic Dystrophy Type 1. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Toward Developing Robust Myotonic Dystrophy Brain Biomarkers using White Matter Tract Profiles Sub-Band Energy and A Framework of Ensemble Predictive Learning.
Kamali, T., Parker, D., Day, J. W., Sampson, J., Deutsch, G. K., & Wozniak, J. R. (2021). Toward Developing Robust Myotonic Dystrophy Brain Biomarkers using White Matter Tract Profiles Sub-Band Energy and A Framework of Ensemble Predictive Learning. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2021, 3838–3841. -
Brief assessment of cognitive function in myotonic dystrophy: multicenter longitudinal study using computer-assisted evaluation.
Deutsch, G. K., Hagerman, K. A., Sampson, J., Dent, G., Dekdebrun, J., Parker, D. M., … Day, J. W. (2022). Brief assessment of cognitive function in myotonic dystrophy: multicenter longitudinal study using computer-assisted evaluation. Muscle & Nerve. -
Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019.
Howe, S. J., Ladipus, D., Hull, M., Yeaw, J., Stevenson, T., & Sampson, J. B. (2022). Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019. Orphanet Journal of Rare Diseases, 17(1), 79. -
Correction: Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019.
Howe, S. J., Lapidus, D., Hull, M., Yeaw, J., Stevenson, T., & Sampson, J. B. (2022). Correction: Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019. Orphanet Journal of Rare Diseases, 17(1), 260. -
Cognitive Impairment Analysis of Myotonic Dystrophy via Weakly Supervised Classification of Neuropsychological Features.
Kamali, T., Deutsch, G. K., Hagerman, K. A., Parker, D., Day, J. W., Sampson, J. B., & Wozniak, J. R. (2022). Cognitive Impairment Analysis of Myotonic Dystrophy via Weakly Supervised Classification of Neuropsychological Features. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2022, 4377–4382. -
Multimodal fusion of neuroimaging and neuropsych data: A machine learning approach to study brain alterations linked with cognitive domains in DM1
Kamali, T., Parker, D., Deutsch, G., Sampson, J., Day, J., & Wozniak, J. (2022). Multimodal fusion of neuroimaging and neuropsych data: A machine learning approach to study brain alterations linked with cognitive domains in DM1. NEUROMUSCULAR DISORDERS. PERGAMON-ELSEVIER SCIENCE LTD. -
Evaluating 2-3 year responses to disease modifying treatment in adults with spinal muscular atrophy
Duong, T., Tang, W., Young, S. D., Parker, D., Wolford, C., Sampson, J., & Day, J. (2022). Evaluating 2-3 year responses to disease modifying treatment in adults with spinal muscular atrophy. NEUROMUSCULAR DISORDERS. PERGAMON-ELSEVIER SCIENCE LTD. -
A concurrent dual analysis of genomic data augments diagnoses: experiences of two clinical sites in the Undiagnosed Diseases Network.
Spillmann, R. C., Tan, Q. K.-G., Reuter, C., Schoch, K., Kohler, J., Bonner, D., … Shashi, V. (2022). A concurrent dual analysis of genomic data augments diagnoses: experiences of two clinical sites in the Undiagnosed Diseases Network. Genetics in Medicine : Official Journal of the American College of Medical Genetics. -
Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial.
Kohler, W., Engelen, M., Eichler, F., Lachmann, R., Fatemi, A., Sampson, J., … Mochel, F. (2023). Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial. The Lancet. Neurology, 22(2), 127–136. -
Exploring Protein Changes in Cerebrospinal Fluid of Spinal Muscular Atrophy Patients Pre-Nusinersen vs. Post-Nusinersen Treatment using Bayesian Machine Learning Algorithms
Kamali, T., Hagerman, K., Duong, T., Parker, D., Young, S., Tang, W., … Day, J. (2022). Exploring Protein Changes in Cerebrospinal Fluid of Spinal Muscular Atrophy Patients Pre-Nusinersen vs. Post-Nusinersen Treatment using Bayesian Machine Learning Algorithms. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Mesial Temporal Enlargement in Adult-Onset Myotonic Dystrophy Type 1
Fecto, F., Parker, D., Sampson, J., Mueller, B., Lim, K., Wozniak, J., … Day, J. (2022). Mesial Temporal Enlargement in Adult-Onset Myotonic Dystrophy Type 1. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Mesial Temporal Enlargement in Adult-Onset Myotonic Dystrophy Type 1
Fecto, F., Parker, D., Sampson, J., Mueller, B., Lim, K., Wozniak, J., … Day, J. (2022). Mesial Temporal Enlargement in Adult-Onset Myotonic Dystrophy Type 1. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial
Koehler, W., Engelen, M., Eichler, F., Lachmann, R., Fatemi, A., Sampson, J., … Adv Study Grp. (2023). Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial. LANCET NEUROLOGY, 22(2), 127–136. -
Participation in a national diagnostic research study: assessing the patient experience.
Rosenfeld, L. E., LeBlanc, K., Nagy, A., Ego, B. K., & McCray, A. T. (2023). Participation in a national diagnostic research study: assessing the patient experience. Orphanet Journal of Rare Diseases, 18(1), 73. -
Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1.
Nutter, C. A., Kidd, B. M., Carter, H. A., Hamel, J. I., Mackie, P. M., Kumbkarni, N., … Swanson, M. S. (2023). Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1. Brain : a Journal of Neurology. -
Genomics Research with Undiagnosed Children: Ethical Challenges at the Boundaries of Research and Clinical Care.
Halley, M. C., Young, J. L., Tang, C., Mintz, K. T., Lucas-Griffin, S., Maghiro, A. S., … Tabor, H. K. (2023). Genomics Research with Undiagnosed Children: Ethical Challenges at the Boundaries of Research and Clinical Care. The Journal of Pediatrics, 113537. -
Genomics Research with Undiagnosed Children: Ethical Challenges at the Boundaries of Research and Clinical Care
Halley, M. C., Young, J. L., Tang, C., Mintz, K. T., Lucas-Griffin, S., Maghiro, A. S., … Undiagnosed Diseases Network. (2023). Genomics Research with Undiagnosed Children: Ethical Challenges at the Boundaries of Research and Clinical Care. JOURNAL OF PEDIATRICS, 261. -
Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
Berndt, S. I., Vijai, J., Benavente, Y., Camp, N. J., Nieters, A., Wang, Z., … Rothman, N. (2023). Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia. -
A Multimodal Neuroimaging Feature Extraction Framework for Biomarker Discovery in Myotonic Dystrophies
Kamali, T., Day, J., Sampson, J., Murad, A., & Chaufty, J. (2023). A Multimodal Neuroimaging Feature Extraction Framework for Biomarker Discovery in Myotonic Dystrophies. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy.
Beaudin, M., Kamali, T., Tang, W., Hagerman, K. A., Dunaway Young, S., Ghiglieri, L., … Day, J. W. (2023). Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy. Journal of Clinical Medicine, 12(20). -
A Phase 3 Clinical Trial of Leriglitazone with Adaptive Placebo-Controlled Treatment Duration in Adults with Cerebral Adrenoleukodystrophy
Fatemi, A., Koehler, W., Eichler, F., Mochel, F., Sadjadi, R., Lund, T., … Martinell, M. (2023). A Phase 3 Clinical Trial of Leriglitazone with Adaptive Placebo-Controlled Treatment Duration in Adults with Cerebral Adrenoleukodystrophy. ANNALS OF NEUROLOGY. WILEY. -
Learning Spectral Fractional Anisotropy and Mean Diffusivity Features as Neuroimaging Biomarkers for Tracking White Matter Integrity Changes in Myotonic Dystrophy Type 1 Patients using Deep Convolutional Neural Networks.
Kamali, T., Day, J. W., Deutsch, G. K., Sampson, J. B., Murad, A., Chaufty, J., … Wozniak, J. R. (2023). Learning Spectral Fractional Anisotropy and Mean Diffusivity Features as Neuroimaging Biomarkers for Tracking White Matter Integrity Changes in Myotonic Dystrophy Type 1 Patients using Deep Convolutional Neural Networks. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2023, 1–4. -
Recurring homozygous ACTN2 variant (p.Arg506Gly) causes a recessive myopathy.
Donkervoort, S., Mohassel, P., O'Leary, M., Bonner, D. E., Hartley, T., Acquaye, N., … Bönnemann, C. G. (2024). Recurring homozygous ACTN2 variant (p.Arg506Gly) causes a recessive myopathy. Annals of Clinical and Translational Neurology.
Practice Locations
Neuromuscular Program at the Neuroscience Health Center Palo Alto, CA
Palo Alto, CANeuromuscular Program at the Neuroscience Health Center
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Stanford Neuroscience Health Center Palo Alto, CA
Palo Alto, CAStanford Neuroscience Health Center
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Neurogenetic Cancer Palo Alto, CA
Palo Alto, CANeurogenetic Cancer
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(208 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records